NeoGenomics (NEO) | Stock Overview & Key Data
NeoGenomics Performance Comparison
Stock Range
Today's Range
Low: $4.80
High: $5.64
on July 29, 2025
52 Week Range
Low: $4.80
High: $19.11
on July 29, 2025
on January 8, 2025
All-Time High: $61.57 on February 15, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$809.5M
EPS
-0.61
P/E Ratio (TTM)
-10.15
Forward P/E
31.45
P/B Ratio
0.91
PEG Ratio
31.45
Div. Yield
N/A
ROE
-8.57%
Beta
1.623
Debt to Equity
68.09
Financial Highlights
Profitability
Gross Margin
43.59%
Operating Margin
-16.56%
Profit Margin
-11.54%
Returns and Earnings
Return on Assets (TTM)
-2.75%
Return on Equity (TTM)
-8.57%
EBITDA
$5.1M
Net Income (TTM)
$-77.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$5.25
Quarterly Revenue Growth (YoY)
7.50%
Quarterly Earnings Growth (YoY)
7.55%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| NeoGenomics NEO | 809.49M Small-cap | -18.22% | -28.18% | -20.21% | -63.97% | -68.16% | -69.42% | -48.58% | -86.77% |
| Thermo Fisher TMO | 180.56B Large-cap | 12.75% | 18.92% | 12.78% | -15.15% | -7.73% | -21.69% | -18.31% | 16.37% |
| Danaher DHR | 145.32B Large-cap | 8.92% | 4.71% | 3.98% | -7.54% | -9.99% | -25.26% | -19.54% | 13.60% |
| Veracyte VCYT | 1.98B Small-cap | 4.08% | -9.47% | -22.02% | -44.94% | -39.49% | 13.29% | -12.29% | -24.36% |
| Grail GRAL | 1.38B Small-cap | -8.18% | -33.64% | -7.31% | 27.93% | 90.40% | 105.67% | 133.38% | 133.38% |
| Neogen NEOG | 1.13B Small-cap | -3.78% | 1.05% | -3.98% | -58.00% | -59.55% | -70.51% | -77.45% | -88.20% |
Ownership & Short Interest
Insider Ownership
1.19%
Institutional Ownership
98.21%
Shares Short
4M
Short Ratio
2.18
Short % of Shares Outstanding
4.58%
Average 10-Day Volume
2M
Average 90-Day Volume
2M
NeoGenomics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in NeoGenomics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is NEO's 52-week high and low?
- In the last 52 weeks, NeoGenomics reached a high of $19.11 (on January 8, 2025) and a low of $4.80 (on July 29, 2025).
- What is the market cap and P/E ratio for NEO?
- Curious about NeoGenomics's size and valuation? Its market capitalization stands at 809.49M. When it comes to valuation, the P/E ratio (trailing twelve months) is -10.15, and the forward P/E (looking ahead) is 31.45.
- Does NEO pay dividends? If so, what's the yield?
- As for dividends, NeoGenomics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are NeoGenomics's main competitors or similar companies to consider before investing?
When looking at NeoGenomics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Thermo Fisher
TMO180.56B Healthcare Diagnostics & Research -21.69% -18.31% Danaher
DHR145.32B Healthcare Diagnostics & Research -25.26% -19.54% Veracyte
VCYT1.98B Healthcare Diagnostics & Research 13.29% -12.29% Grail
GRAL1.38B Healthcare Diagnostics & Research 105.67% 133.38% Neogen
NEOG1.13B Healthcare Diagnostics & Research -70.51% -77.45% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for NeoGenomics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of NeoGenomics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -8.57%, the Debt to Equity ratio from the most recent quarter is 68.09, and its Gross Profit Margin stands at 43.59%.
- What is the recent revenue and earnings growth for NEO?
- Looking at NeoGenomics's growth, its revenue over the trailing twelve months (TTM) was $672M. Compared to the same quarter last year (YoY), quarterly revenue grew by 7.50%, and quarterly earnings saw a YoY growth of 7.55%.
- How much of NEO stock is held by insiders and institutions?
- Wondering who owns NeoGenomics stock? Company insiders (like executives and directors) hold about 1.19% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 98.21%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.